Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome

This is a prospective, monocentric, proof of concept study aims to identify in prostate cancer patients, a potential relationship between CTC-PSMA positivity and 18F-PET-PSMA results as well as patient outcome. Patients with 18F-PET-PSMA indication will perform imaging extension work-up as part of current practice. If they agree to participate in the study, a blood sample will be performed prior to the 18F-PET-PSMA standard imaging (T1). In order to evaluate the potential relationship between CTC-PSMA and 18F-PET-PSMA imaging, the study will be presented to all patients seen in consultation

Trial Details

NCT ID
NCT06917781
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Patients with 18F-PET-PSMA indication
Locations (sample)
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Age ≥ 18 years
  • Histologically confirmed adenocarcinoma of the prostate
  • Indication for 18F-PET-PSMA imaging
  • Signed written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →